Moderna share price doubles on melanoma vaccine trial success
Company’s melanoma cancer vaccine being developed with Merck
We haven't written up this one. Financial Times has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
- STAT+: Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial statnews.com
- Merck, Moderna declare Phase 3 success for personalized mRNA cancer vaccine endpoints.news
- Moderna and Merck's personalized skin cancer vaccine cleared its first large-scale trial qz.com
- Personalized cancer vaccine from Moderna, Merck shows promise in first late-stage melanoma trial cnbc.com
